Clinical Trial Update: Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics [Phase 3]

View source ↗

Summary

Phase 3 immunosafety study of recombinant human insulins in type 1 diabetes was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Snippet

Sponsor: Wockhardt | Conditions: Type I Diabetes | Phase 3 | Status: TERMINATED